Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | CASR | P41180 | 7/20 | 0.56 |
| ▸ | MEN1 | O00255 | 5/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | SENP5 | Q96HI0 | 1/20 | 0.53 |
| ▸ | SENP2 | Q9HC62 | 1/20 | 0.53 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14074103 | 1.00 | RAB9A (0.65) | RAB9ANPC1SMN1; SMN2CASRMEN1 | |
| SCHEMBL2530312 | 0.81 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL14074104 | 0.79 | SMN1; SMN2 (0.57) | RAB9ANPC1SMN1; SMN2CASRMEN1 | |
| SCHEMBL3924558 | 0.78 | CASR (0.69) | SMN1; SMN2CASRMEN1KMT2ALMNA | |
| SCHEMBL8199156 | 0.77 | MAPT (0.54) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4999962 | 0.77 | MAPT (0.54) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL3960599 | 0.76 | SMN1; SMN2 (0.55) | SMN1; SMN2CASRMEN1KMT2A | |
| SCHEMBL8203892 | 0.76 | SMN1; SMN2 (0.55) | SMN1; SMN2CASRMEN1KMT2A | |
| SCHEMBL6123167 | 0.75 | ALDH1A1 (0.74) | RAB9ANPC1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL29684366 | 0.74 | SMN1; SMN2 (0.64) | RAB9ANPC1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221101-A1 | Calcium receptor modulating agents | AMGEN INC. (US) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221101-A1 | Calcium receptor modulating agents | CASR, RYR1, RYR2 | RAB9A 1512/4885NPC1 1243/4885SMN1; SMN2 2433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.